How Walmart plans to save on generics June 03, 2016By Christine BlankWalmart has decided to put all its eggs in a really big basket. Pharmacists seek fairness in generics reimbursement May 31, 2016By Christine BlankPBMs have dodged state-mandated requirements for transparency in generics drug pricing, so many states are rewriting their laws. FDA generics backlog improves, although criticism continues May 03, 2016By Christine BlankWhile many groups are criticizing the FDA backlog of generic drug approvals, the agency has released the numbers on approvals and tentative approvals for 2015. Generic treatment for chronic myeloid leukemia could save millions May 03, 2016By Christine BlankFive years of imatinib treatment for CML = >$100,000 saved per patient. Biosimilars' savings may reach $100 billion by 2020 March 30, 2016By Christine BlankThe use of biosimilars in the European Union and the United States may yield huge savings to healthcare systems over the next five years U.S. physicians start to embrace prescribing of biosimilars March 24, 2016By Christine BlankPhysicians are beginning to understand the value of biosimilars, particularly those who are high prescribers of biologics and therefore familiar with biosimilars. Legislators call for transparency in generic drug pricing March 01, 2016By Christine BlankSixteen members of Congress are urging passage of the MAC Transparency Act and greater reimbursement transparency for the big federal health programs. Biosimilar offers hope of lower-cost treatment of autoimmune diseases February 26, 2016By Christine BlankHere's the latest on the second biosimilar in line to receive FDA approval. Do chains or independent pharmacies offer the best generic pricing? February 01, 2016By Christine BlankAfter secretly shopping at 200 stores in six states, "Consumer Reports" announced its findings, and they make for very interesting reading. Generic drugs: How to keep those cost savings coming February 01, 2016By Christine BlankThe U. S. healthcare system saved a record $254 billion from generic drugs in 2014 and $1.68 trillion from 2005 to 2014, but much more can be done.